Aakanksha M Chawda, a promoter of Telangana-based Oxygenta Pharmaceutical Limited, disclosed the sale of a 2.74% stake in the company in compliance with SEBI takeover regulations. The move reduces her holding to 1.54% and was reported to the BSE.
In a regulatory move, Aakanksha M Chawda, a promoter of Oxygenta Pharmaceutical Limited, a Telangana-based pharmaceutical firm, has reported the sale of 10,12,800 equity shares, representing 2.74% of the company’s shareholding, as per the norms outlined by the Securities and Exchange Board of India (SEBI) under Regulation 29(2) and 29(3) of the Substantial Acquisition of Shares and Takeovers (SAST) Regulations, 2011.
The transaction was conducted on April 22, 2025, as per a Memorandum of Understanding dated September 30, 2024. Prior to the transaction, Chawda held 15,82,500 shares, equating to 4.28% of the total shareholding. Post-sale, her stake stands at 5,69,700 shares or 1.54% of the total diluted voting capital.
The equity capital of the company remains unchanged at 3,69,83,500 equity shares valued at Rs. 10 each, amounting to Rs. 36.98 crore. The disclosure was formally submitted to BSE Limited, where the company is listed, for compliance and record-keeping.
The transaction was executed through an agreed off-market transfer, aligning with regulatory requirements for transparency in promoter-level changes in shareholding.
This development signifies a notable shift in promoter stakeholding in one of Telangana’s active pharmaceutical entities.
For more information, Click Here.
